In this hyperactivation, PTEN, a tumour suppressor, commonly has loss-of-function mutations, and PIK3CA, encoding the catalytic subunit of PI3K, has gain-of-function mutations, leading to unchecked endpoints of PIP3 and then AKT activation [[82], [83], [84]]. This evidence concerns the gene PIK3CA and neoplasm.